Lactitol
Also known as: Lactitol monohydrate
A lactose-derived osmotic laxative with a defined adult constipation indication, formulation-specific labeling and important contraindications.

Lactitol is an osmotic disaccharide laxative. FDA approved a defined oral-solution product for adult chronic idiopathic constipation in 2020. In its pivotal analysis, about 25% met a sustained bowel-response endpoint versus 13% with placebo. Galactosemia, suspected mechanical obstruction and the timing of other oral medicines require particular attention.4, 1, 2
- The pivotal analysis included 594 adults, and the primary endpoint used the first 12 weeks of a six-month treatment period.1, 2
- FDA's review identifies 20 g lactitol as equivalent to 21 g lactitol monohydrate in the assessed formulation.2
- The label contraindicates use in known or suspected mechanical gastrointestinal obstruction and galactosemia.1
What is Lactitol?
FDA describes lactitol as a synthetic lactose derivative consisting of linked galactose and sorbitol. It draws water into the intestine and is minimally absorbed systemically. The assessed medicine uses lactitol monohydrate powder, with labeled amounts expressed as lactitol.2, 1
Where it comes from
Natural sources
- Lactose is the starting compound for the synthetic derivative described by FDA.
How it's made
The evaluated oral medicine is formulated with lactitol monohydrate powder for reconstitution.
What it does in products
Benefits
Sustained bowel-response improvement in adult CIC
moderate evidenceThe response definition combines frequency, change from baseline and persistence.1, 2
Responders had at least three complete spontaneous bowel movements per week and an increase of at least one from baseline for nine of the first 12 weeks, including three of the final four. Response was 25% with lactitol and 13% with placebo, a 12-percentage-point difference. This remains an adult, product-specific result.
Evidence scope and limitations
FDA's adult CIC approval and trial review, the August 2021 oral-product label and an older adult-constipation meta-analysis.
- The original phase III dataset was assessed through FDA's trial reports and label. Its final analysis population reflects documented data-quality exclusions.
- The 2014 meta-analysis was checked through its original abstract. It contains several uncontrolled studies and authors affiliated with a sweetener manufacturer.
- The public application API still listed the 2021 label at this check. Retail availability, other countries' formulations and separate liver-disease protocols were outside this assessment.
Evidence last checked: 2026-11-16
Side effects & safety
Safety considerations
- The label describes insufficient pregnancy data and uncertain breastfed-infant exposure. Clinical assessment should include the need for treatment and the particular patient's circumstances.
- The label warns that lactitol may reduce absorption of other oral medicines and specifies at least two hours of separation before or after this product. A pharmacist can check the complete regimen.
- Not for: People with known or suspected mechanical gastrointestinal obstruction.
- Not for: People with galactosemia.
Amounts studied & product use
These figures describe research or common product use, not a personal dose or treatment recommendation.
In the assessed adult constipation formulation
The phase III program evaluated 20 g/day of lactitol, corresponding to 21 g of the monohydrate preparation. Its label allows a reduction to 10 g/day for persistent loose stools. These describe the studied product and labeling. The prescription and product-specific directions govern individual use.
Regulatory status
- FDA approved NDA 211281 on February 12, 2020 for chronic idiopathic constipation in adults. The public application record checked for this guide lists an August 2021 labeling supplement. The cited label retains that date. Pediatric safety and effectiveness remain unestablished in that label.
Read the analysis population and the mass basis
FDA's review describes removal of records affected by site misconduct, lost data, duplicate enrollment and other eligibility or baseline-data problems. The final 594-person analysis is the relevant denominator for the labeled placebo comparison. It deserves attention alongside the response percentage.
The older 2014 meta-analysis pooled 11 studies, including five single-arm studies and only one placebo-controlled trial. Its before-and-after improvements carry different information from the later pivotal placebo comparison. The FDA review also resolves the 20 g versus 21 g wording through the lactitol and monohydrate mass basis.
2, 1, 3Frequently asked questions
Does the monohydrate wording describe a larger tested amount of lactitol?
FDA's review describes the same assessed preparation as 21 g monohydrate supplying 20 g lactitol. Check the label's mass basis before comparing reported amounts across formulations.2
The bottom line
Interpret lactitol through the defined adult indication, final trial population and exact product label.
References
- Pizensy (lactitol) for oral solution — prescribing information. U.S. Food and Drug Administration / Braintree Laboratories (2021) · ingredient monograph · NDA 211281/S-001; revised August 2021; reference ID 4842742; indication, trial, contraindications, interactions and safety checked. This remains the latest label document listed in the public Drugs@FDA API record checked November 16, 2026.
- NDA 211281 — Multi-Disciplinary Review and Evaluation of lactitol. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (2020) · government guidance · NDA 211281; reference ID 4560397; released in the 2020 approval package, with internal review dates retained in the document; clinical analysis population and 20 g lactitol/21 g monohydrate equivalence checked
- Miller LE, Tennilä J, Ouwehand AC. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clinical and Experimental Gastroenterology (2014) · meta analysis · PMID 25050074; DOI 10.2147/CEG.S58952; 2014, 7:241–248; original abstract and author affiliations checked, full text access limited
- NDA 211281 — Approval letter for Pizensy (lactitol). U.S. Food and Drug Administration (2020) · government guidance · NDA 211281; February 12, 2020; reference ID 4560427; adult chronic idiopathic constipation indication checked
Revision history
- Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.